In a significant development for cardiovascular medicine, the highly anticipated phase III LIBREXIA ACS trial has concluded that the investigational factor XIa inhibitor milvexian failed to reduce the risk of recurrent cardiovascular (CV) events in patients recently hospitalized for acute coronary syndrome (ACS). While the drug did not achieve its primary efficacy endpoint, its favorable safety profile—demonstrating no significant increase in major bleeding—provides a nuanced perspective on the future of this therapeutic class.
The findings, presented at the European Society of Cardiology (ESC) Congress in Munich and published simultaneously in the New England Journal of Medicine, mark a pivotal moment in the search for safer anticoagulation strategies.
Main Facts: The Efficacy Gap
The LIBREXIA ACS study was designed to determine if adding milvexian (25 mg twice daily) to standard-of-care antiplatelet therapy would provide a protective buffer against subsequent cardiovascular events. The primary efficacy endpoint was a composite of CV death, myocardial infarction (MI), or ischemic stroke.
After a median follow-up of 12.2 months, the results were sobering. A primary endpoint event occurred in 384 patients (5.4%) in the milvexian group, compared to 365 patients (5.1%) in the placebo group. The hazard ratio (HR) stood at 1.05 (95% CI 0.91-1.21), with a p-value of 0.50, indicating no statistically significant benefit to the investigational drug.
Despite the enrollment of 14,194 patients across nearly 900 international sites, the trial failed to demonstrate that factor XIa inhibition provided the additional protection clinicians and researchers had hoped for in high-risk ACS populations.
Chronology: From High Hopes to Early Termination
The journey of the LIBREXIA ACS trial was characterized by high clinical expectations followed by a swift, data-driven conclusion.
- Trial Inception and Design: The study aimed to test whether the inhibition of factor XIa—a component of the coagulation cascade hypothesized to contribute to thrombosis without significantly impairing hemostasis—could safely augment standard antiplatelet therapy.
- Enrollment: Between 2023 and 2025, researchers recruited over 14,000 patients who had experienced an ACS event and possessed at least two additional cardiovascular risk factors.
- The Interim Analysis (November 2025): As the study progressed, a pre-planned interim analysis was conducted based on 556 adjudicated efficacy endpoints. The Data and Safety Monitoring Board (DSMB) reviewed the data and reached a critical conclusion: the trial was "unlikely to meet the primary efficacy endpoint."
- Trial Suspension: Following the DSMB recommendation, the developer officially halted the trial in November 2025, citing futility.
- Presentation and Publication (2026): Final results were formally unveiled at the ESC Congress and published in the NEJM, confirming that the early cessation was justified by the lack of observed clinical benefit.
Supporting Data: Examining the Safety and Efficacy
While the efficacy results were disappointing, the safety data offered a different narrative. A major concern with any anticoagulant added to antiplatelet therapy is the potential for increased bleeding.
The Safety Profile
Study author P. Gabriel Steg, MD, of Bichat-Claude Bernard Hospital and Paris Diderot University, highlighted that milvexian successfully navigated the primary safety metric. The trial monitored Bleeding Academic Research Consortium (BARC) type 3c or 5 bleeding—the most severe forms, including intracranial or fatal hemorrhage.
The occurrence of these events was nearly identical across groups:
- Milvexian Group: 23 patients (0.3%)
- Placebo Group: 22 patients (0.3%)
- P-value: 0.88
This lack of increased bleeding risk is an important finding, suggesting that the dose of milvexian tested does not tip the delicate balance of hemostasis toward dangerous bleeding, even when combined with potent antiplatelet agents.
Trial Demographics and Background Therapy
The cohort was intentionally high-risk. More than half of the participants carried three or more risk factors. Notably, 92% of the patients underwent revascularization, and the vast majority were on prolonged dual antiplatelet therapy (DAPT). This high level of background protection may have created a "ceiling effect," where the incremental benefit of an additional anticoagulant became difficult to distinguish.
Official Responses and Clinical Commentary
The medical community has reacted with a mix of caution and analytical rigor. Dr. Marc S. Sabatine of Brigham and Women’s Hospital, serving as an ESC discussant, provided a measured evaluation of the study.
"The results were clear," Sabatine stated. "There was no benefit for milvexian in this study." He noted that the confidence intervals were sufficiently narrow to rule out any meaningful clinical benefit for this specific population at this dosage.
Sabatine further posited that the lack of increased bleeding—while objectively positive—might also hint at a lack of potent efficacy. "The optimal degree of factor XI or XIa inhibition that is needed in different patient populations remains undefined," he noted.
The trial’s failure to demonstrate efficacy does not necessarily invalidate the entire class of factor XIa inhibitors. Researchers are currently looking at other ongoing trials to see if different indications or patient populations might respond differently to the mechanism.
Implications: The Future of Factor XIa Inhibition
The conclusion of LIBREXIA ACS has profound implications for the ongoing clinical development of milvexian and other similar agents.
Ongoing Trials: AF and Stroke
The development program for milvexian is not dead. The drug is currently being tested in two other large-scale phase III trials: LIBREXIA AF (atrial fibrillation) and LIBREXIA STROKE (secondary stroke prevention).
Dr. Steg emphasized that the safety profile observed in the ACS trial provides a "green light" for these ongoing studies. Because the DSMB recommended that these other trials continue as planned, the scientific community remains optimistic that factor XIa inhibition may find its therapeutic niche in conditions where the pathophysiology of thrombosis differs from that of ACS.
Scientific Unmet Need
Despite the success of current DAPT regimens and PCI techniques, the residual risk of cardiovascular events remains high. As Dr. Steg noted, "The incidence of MACE was high, and there remains an unmet need." The failure of milvexian in this specific trial highlights the complexity of preventing ischemic events without inducing hemorrhage.
Lessons Learned
The LIBREXIA ACS experience serves as a reminder of the challenges in cardiovascular trial design. Choosing the correct dose, the correct population, and the correct background therapy is a delicate process. The fact that another factor XIa inhibitor, asundexian, previously showed mixed results—failing in AF but showing promise in stroke prevention—underscores that we are still in the early stages of understanding the clinical utility of this drug class.
In summary, while LIBREXIA ACS did not deliver the breakthrough clinicians were hoping for, it has provided a clean, high-quality dataset that will inform the design of future trials. The focus now shifts to the 2026 data readouts for AF and stroke, which will ultimately determine whether factor XIa inhibitors will become a new cornerstone in the anticoagulant landscape or remain a promising theory yet to find its clinical home.
For now, the medical community remains in a period of "watchful waiting," eager to see if the therapeutic promise of factor XIa inhibition can be realized in other, perhaps more appropriate, cardiovascular contexts.
